STOCK TITAN

Enovix issues stockholders 1 warrant per 4 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Enovix distributed warrants on November 18, 2026, to common stockholders of record on November 13, at one warrant for every four common shares, rounded down. Eligible holders of the 2028 and 2030 convertible notes also receive warrants on a pass-through basis, without converting their notes. The company’s legal opinion covers issuance of up to 62,329,657 shares upon warrant exercise.

Each warrant allows its holder to buy one share for $3.00 in cash, or exercise 333 warrants by surrendering $1,000 principal amount of designated 2028 Notes. The 2030 Notes are not eligible for exercise payment. Enovix receives cash only from cash exercises; accepted 2028 Notes are canceled.

The warrants are scheduled to expire on April 28, 2028, but may expire earlier if the common stock’s VWAP meets the initially $3.30 trigger on 20 qualifying days within a 30-trading-day period. The company may set a later alternate expiration date subject to additional price conditions. Trading under ENVXW is expected to begin November 19, subject to applicable approvals.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Warrant distribution ratio 1 warrant per 4 shares For common stockholders of record on November 13, 2026; fractional warrants are rounded down.
Warrants distributed Approximately 62.3 million warrants Includes around 54.4 million to common stockholders and 7.9 million to convertible noteholders.
Shares issuable upon exercise Up to 62,329,657 shares Common shares covered by the legal opinion in connection with warrant exercises.
Exercise price $3.00 per warrant Cash exercise price for one common share, subject to adjustments under the warrant agreement.
Note exercise alternative $1,000 principal amount for 333 warrants The company initially designated the 2028 Notes for exercise payment.
Early expiration trigger $3.30 VWAP; 20 qualifying days in 30 trading days The trigger price is initially $3.30 and is subject to adjustment.
Scheduled expiration April 28, 2028 Warrants may expire earlier if the early expiration price condition occurs.
Potential exercise consideration Approximately $169.1 million If all approximately 62.3 million warrants are exercised; excludes warrants held by directors and executive officers and may include cash and 2028 Notes.
pass-through basis financial
"noteholders also receive warrants on a pass-through basis"
volume-weighted average price (VWAP) technical
"the Daily VWAP of the Common Stock"
Volume-weighted average price (VWAP) is the average price of a security over a trading period where each trade’s price is weighted by how many shares were traded, so larger trades pull the average more than tiny ones. Investors and traders use VWAP as a benchmark to judge whether a trade was executed at a favorable price—similar to checking whether you paid more or less than the typical price when most people were buying or selling.
Early Expiration Price Condition technical
"Upon the occurrence of the Early Expiration Price Condition"
Designated Notes financial
"delivery of certain issued and outstanding notes designated by the Company"
Additional Price Conditions technical
"expiration shall be conditioned on the Additional Price Conditions"
anti-dilution adjustments financial
"subject to certain anti-dilution adjustments"
Anti-dilution adjustments are changes made to the ownership stakes or value of an investment to protect investors from having their shares become less valuable if the company issues new shares at a lower price. Imagine buying a piece of a pie, and then the pie is cut into more slices without increasing in size—these adjustments help ensure your slice still retains its worth. They matter to investors because they help preserve the value of their investment when the company’s share price drops.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many warrants will Enovix distribute to ENVX holders?

Enovix expects to distribute approximately 62.3 million warrants, including around 54.4 million to common stockholders and 7.9 million to convertible noteholders. Common stockholders of record on November 13, 2026, receive one warrant for every four shares, rounded down.

How can ENVX warrant holders pay the exercise price?

Holders may exercise with $3.00 in cash per warrant or with designated 2028 Notes. For the note option, $1,000 principal amount of 2028 Notes can be delivered for 333 warrants. The 2030 Notes are not eligible for exercise payment.

When do ENVX warrants expire early?

The warrants may expire early if the stock meets the initially $3.30 VWAP trigger on 20 qualifying days in a 30-trading-day period. The warrant agreement provides for expiration on the scheduled trading day immediately following the condition date, unless Enovix sets a later alternate date subject to additional price conditions.

How much could Enovix receive if the warrants are exercised?

If all approximately 62.3 million warrants are exercised, Enovix estimates approximately $169.1 million in aggregate exercise consideration, excluding warrants held by directors and executive officers. The amount would consist of cash and 2028 Notes surrendered at face value; actual cash proceeds depend on exercise levels and payment choices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001828318 0001828318 2026-11-18 2026-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 18, 2026

 

 

 

Enovix Corporation

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39753   85-3174357
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

3501 W Warren Avenue 

Fremont, California

  94538
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (510) 695-2350 

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ENVX   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

As previously disclosed, on October 28, 2026, Enovix Corporation, a Delaware corporation (the “Company”), announced that the Board of Directors of the Company declared a distribution (the “Warrant Distribution”) to the holders of record of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), in the form of warrants to purchase shares of Common Stock (the “Warrants”). The Warrants were issued on the terms and conditions described in the Warrant Agreement (as defined below and attached as an exhibit hereto) and are being distributed on November 18, 2026, to the holders of record of Common Stock as of the close of business on November 13, 2026 (the “Record Date”).

 

Pursuant to the terms of the Warrant Agreement, dated as of November 18, 2026, between the Company, Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., as Warrant Agent (the “Warrant Agent”) (such agreement, the “Warrant Agreement”), each holder of record of Common Stock as of the Record Date will receive one Warrant for every four shares of Common Stock (rounded down to the nearest whole number for any fractional Warrant). Holders (“other eligible recipients”) of our 3.00% Convertible Senior Notes due 2028 (the “2028 Notes”)  and the Company’s 4.75% Convertible Senior Notes due 2030 (collectively with the 2028 Notes, the “Convertible Notes”) will also receive, at the same time and on the same terms as holders of Common Stock, Warrants without having to convert such other eligible recipient’s Convertible Notes as if each such holder of Convertible Notes held a number of shares of Common Stock equal to the product of (i) the conversion rate applicable to the Convertible Notes in effect on the Record Date, and (ii) the aggregate principal amount (expressed in thousands) of Convertible Notes held by such noteholder on such date.

 

Each Warrant will entitle the holder to purchase, at the holder’s sole and exclusive election, at an exercise price of $3.00 per Warrant (the “Warrant Exercise Price”), one share of Common Stock payable in cash. The Warrants may also be exercised, at the election of the holder, by delivery of certain issued and outstanding notes that may be designated by the Company from time to time pursuant to the terms of the Warrant Agreement (the “Designated Notes”) by delivering an amount equal to $1,000 principal amount of Designated Notes to exercise up to 333 Warrants (subject to certain adjustments). The Company has initially designated the 2028 Notes as Designated Notes.

 

Unless the Early Expiration Price Condition (defined below) is met, the Warrants will expire and cease to be exercisable at 5:00 p.m. New York City time on the date (the “Expiration Date”) which is (i) April 28, 2028 or (ii) if the Early Expiration Price Condition occurs, the Early Expiration Date, where “Early Expiration Date” means either (x) the first Scheduled Trading Day (defined below) immediately following the Early Expiration Price Condition Date (defined below) (subject to the terms of the Warrant Agreement) (the “Scheduled Early Expiration Date”) or (y) if the Company elects to set an Alternate Early Expiration Date (defined below), such Alternate Early Expiration Date.

 

Upon the occurrence of the first 30 consecutive Trading Day (defined below) period (the “Reference Period”) that includes 20 Qualifying Trading Days (defined below) (whether or not consecutive) the first of which 20 Qualifying Trading Days must fall on or after the first Trading Day immediately following the distribution date of the Warrants (the “Early Expiration Price Condition”, and the last of such 20 Qualifying Trading Days (whether or not consecutive) to occur, the “Early Expiration Price Condition Date”), the Expiration Date will automatically accelerate to the Scheduled Early Expiration Date, unless the Company sets an Alternate Early Expiration Date (defined below) in accordance with the provisions described below and as further described in the Warrant Agreement, in which case the Early Expiration Date will be such Alternate Early Expiration Date. In the event of an early expiration of the Warrants, Warrants will be exercisable until 5:00 p.m. New York City time on the Early Expiration Date. If the Early Expiration Price Condition occurs, the Company will make a public announcement by issuance of a press release to that effect as promptly as practicable after market close on the Early Expiration Price Condition Date setting forth the Early Expiration Date or an Alternate Early Expiration Date. Subject to applicable laws and regulations and the terms of the Warrant Agreement, including the occurrence of the Early Expiration Price Condition or the Additional Price Conditions (defined below), the Warrants may be exercised at any time starting on the date of issuance until 5:00 p.m. New York City time on the Expiration Date.

 

1 

 

 

The Company may, in its sole discretion, elect to set the Early Expiration Date on a Scheduled Trading Day falling after the Scheduled Early Expiration Date (such date, an “Alternate Early Expiration Date”). In order to exercise the right to set an Alternate Early Expiration Date, the Company shall, no later than the fifth Qualifying Trading Day (whether or not consecutive) occurring in any 20 consecutive Trading Day period ending on or before the next following Early Expiration Price Condition Date (if any), make a public announcement by issuance of a press release that the Company is reserving the right to set an Alternate Early Expiration Date in the event the Early Expiration Price Condition does occur. If the Company sets an Alternate Early Expiration Date, the expiration of the Warrants on such Alternate Early Expiration Date shall be conditioned on (x) in respect of each of the two consecutive Scheduled Trading Days immediately preceding such Alternate Early Expiration Date, no Market Disruption Event (as defined in the Warrant Agreement) occurring and (y) the Daily VWAP (defined below) on each of such two consecutive Scheduled Trading Days immediately preceding such Alternate Early Expiration Date being at least equal to the quotient obtained by dividing the Warrant Exercise Price by the then-current Warrant Exercise Rate (as defined in the Warrant Agreement) (the “Additional Price Conditions”). As promptly as practicable after close on the Scheduled Trading Day immediately preceding the Alternate Early Expiration Date, the Company will make a public announcement by issuance of a press release as to whether the Additional Price Conditions are met. The Company may, in its sole discretion, postpone such Alternate Early Expiration Date to a new Alternate Early Expiration Date (which, for the avoidance of doubt, shall be conditional upon the Additional Price Conditions in respect of the Alternate Early Expiration Date so postponed). The Company may, in its sole discretion, postpone further (on one or more occasions) such Alternate Early Expiration Date of the Warrants to a new Alternate Early Expiration Date (which, for the avoidance of doubt, shall be conditional upon the Additional Price Conditions with respect to the Alternate Early Expiration Date as so postponed). The Company will make a public announcement of any such postponement by issuance of a press release as promptly as practicable after the close of regular market hours of Nasdaq on the Scheduled Trading Day immediately preceding the Alternate Early Expiration Date to be so postponed. If the Additional Price Conditions are not met as to an Alternate Early Expiration Date specified by the Company, unless the Company sets a new Alternate Early Expiration Date as set forth in the preceding paragraph (an “Alternate Early Expiration Date Annulment”), the Expiration Date will remain April 28, 2028 unless another Early Expiration Price Condition Date subsequently occurs. The definitions of Early Expiration Price Condition, Early Expiration Price Condition Date and Reference Period are subject to appropriate adjustment as set forth in the Warrant Agreement in the event of an Alternate Early Expiration Date Annulment.

 

All or any part of the Warrants may be exercised prior to 5:00 p.m. New York City time on the Expiration Date (as it may be adjusted) by delivering to the Warrant Agent a duly executed notice of election and the Warrants being exercised, and payment of the Warrant Exercise Price in cash or, if there are Designated Notes, by delivery of Designated Notes.

 

For the purposes of the foregoing, “Daily VWAP” of a share of Common Stock (or a Warrant or other security) on any date of determination means (i) in the case of a share of Common Stock, for any day on which trading in the Common Stock generally occurs on the Nasdaq Global Select Market (the “Exchange”) (or, if the Common Stock is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock on such day), the per-share volume-weighted average price in the consolidated tape system during regular market hours as displayed under the headings “Calculation: Bloomberg” and “VWAP” on Bloomberg page “ENVX US Equity AQR” (or its equivalent successor if such page or setting is not available) in respect of such day, (ii) in the case of a Warrant, for any day on which trading in the Warrant generally occurs on the Exchange (or, if the Warrant is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Warrants on such day), the per-warrant volume-weighted average price in the consolidated tape system during regular market hours as displayed under the headings “Calculation: Bloomberg” and “VWAP” on Bloomberg page “ENVXW US Equity AQR” (or its equivalent successor if such page is not available) in respect of such day, and (iii) in the case of any other security, for any day on which trading in such security generally occurs on the Exchange (or, if the security is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of such security on such day), the per-share volume-weighted average price in the consolidated tape system during regular market hours as displayed on Bloomberg page “AQR” for such security in respect of such day. If such information is not so available for the Common Stock or such Warrant or other security, the Daily VWAP on such date shall be the last reported sale price for the Common Stock or such Warrant or other security on such day.

 

2 

 

 

A “Trading Day” for the purposes of the foregoing definition means a day on which the Common Stock (or Warrant or other security, as the case may be) (i) at the close of regular way trading (not including after-hours or extended market trading) is not suspended from trading on the Exchange or, if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange, any U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock (or Warrant or such other security, as the case may be) at the close of business, and (ii) has traded at least once regular way on the Exchange or, if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange, such other U.S. national securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock (or Warrant or such other security, as the case may be); provided that if the Common Stock (or Warrant or such other security, as the case may be) is not so listed or traded, “Trading Day” means a Business Day (as defined in the Warrant Agreement).

 

A “Qualifying Trading Day” for purposes of the foregoing means any S+W Trading Day (defined below) on which the Daily VWAP of the Common Stock on such Trading Day is at least equal to the Early Expiration Trigger Price (defined below) in effect on the last day of the Reference Period (subject to the conditions and limitations set forth in the Warrant Agreement). An “S+W Trading Day” means any day which is a Trading Day for both the Common Stock and the Warrants.

 

A “Scheduled Trading Day” means a day that is scheduled to be a Trading Day on the principal U.S. national or regional securities exchange on which the Common Stock is listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, the principal market on which the Common Stock is admitted for trading. If the Common Stock is not so listed or admitted for trading, “Scheduled Trading Day” means a Business Day.

 

The “Early Expiration Trigger Price” is initially equal to $3.30, subject to certain adjustments.

 

The number of shares of Common Stock issuable upon exercise of the Warrants is subject to certain anti-dilution adjustments, including for stock dividends, splits, subdivisions, reclassifications and combinations, other distributions and spin-offs, and shareholder rights plans. In addition, the Warrant Exercise Rate may be voluntarily increased by the Company from time to time.

 

The Warrants are expected to commence trading on the Nasdaq Stock Market LLC under the ticker “ENVXW” on November 19, 2026.

 

The foregoing description of the Warrants and the Warrant Agreement is only a summary and is qualified in its entirety by reference to the complete description of the terms of the Warrants set forth in the Warrant Agreement (including the Form of Warrant attached thereto), which is filed as an exhibit to this Form 8-K. In connection with the Warrant Distribution, the Company is filing a prospectus supplement, dated November 18, 2026, pursuant to the Company’s existing shelf registration statement on Form S-3, declared effective on November 9, 2026, registering up to $500,000,000 of shares of Common Stock, including the shares of Common Stock to be issued upon exercise of the Warrants, under the Securities Act of 1933, as amended (the “Securities Act”).

 

3 

 

 

Item 7.01 Regulation FD Disclosure.

 

On November 18, 2026, the “Company” issued a press release announcing the Warrant Distribution to its shareholders and other eligible recipients as of the November 13, 2026 Record Date. The press release is attached as Exhibit 99.1 to this Form 8-K.

 

Also on November 18, 2026, the Company posted a further FAQ regarding the Warrant Distribution to the Company’s website (the “FAQ”). The FAQ is attached as Exhibit 99.2 to this Form 8-K. The Company previously announced the Warrant Distribution on October 28, 2026 and published an initial set of questions and answers on its website, which was furnished as Exhibit 99.2 to the Company’s Form 8-K filed on October 28, 2026.

 

The information furnished in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

No Offer or Solicitation

 

This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A Form 8-A registration statement and prospectus supplement describing the terms of the Warrants were filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2026 and are available on the SEC’s website located at http://www.sec.gov. Holders of Company common stock should read the prospectus supplement carefully, including the Risk Factors section included and incorporated by reference therein. This communication contains a general summary of the Warrants. Please read the Warrant Agreement as it contains important information about the terms of the Warrants.

 

Forward-Looking Statements

 

This Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act about the Company, the Warrants and the Warrant Distribution. Forward-looking statements generally relate to future events and can be identified by words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, should, would and similar expressions that convey uncertainty about future events or outcomes. Actual results and outcomes could differ materially from these forward-looking statements as a result of certain risks and uncertainties, including, without limitation, those risks and uncertainties and other potential factors set forth in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed annual report on Form 10-K and quarterly reports on Form 10-Q and other documents that the Company has filed, or that it will file, with the SEC. Any forward-looking statements made by the Company in this Form 8-K, including any forward-looking statements made by the Company in any of the exhibits to this Form 8-K, speak only as of the date on which they are made and subsequent events may cause these expectations to change. The Company disclaims any obligations to update or alter these forward-looking statements in the future, whether as a result of new information, future events or otherwise, except as required by law.

 

4 

 

 

Item 9.01 Financial Statements and Exhibits.

 

On November 18, 2026, Arnold & Porter Kaye Scholer LLP delivered an opinion (the “Opinion”) to the Company in connection with the Company’s issuance of up to 62,329,657 shares of Common Stock upon exercise of the Warrants. Such shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (No. 333-299760) (the “Registration Statement”), which was declared effective on November 9, 2026, including the prospectus, dated November 9, 2026, and the prospectus supplement, dated November 18, 2026, as the same may be amended or supplemented. The Opinion is being filed herewith as Exhibit 5.1, and thereby automatically incorporated by reference into the Registration Statement, in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

 

(d) Exhibits

 

Exhibit Number   Description
4.1     Warrant Agreement (including Form of Warrant), dated November 18, 2026, between the Company, Computershare Inc., a Delaware corporation, and Computershare Trust Company, N.A., as Warrant Agent.
5.1     Opinion of Arnold & Porter Kaye Scholer LLP
23.1     Consent of Arnold & Porter Kaye Scholer LLP (included in Exhibit 5.1).
99.1     Press Release dated November 18, 2026
99.2     Warrant Dividend Distribution FAQ dated November 18, 2026
104     Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

5 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Enovix Corporation
     
Date: November 18, 2026 By: /s/ Ryan Benton
    Ryan Benton
Interim Chief Executive Officer and Chief Financial Officer

 

6 

 

Exhibit 99.1

 

 

 

Enovix Distributes Dividend of Warrants to Stockholders

 

FREMONT, Calif., November 18, 2026 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix” or the “Company,” Nasdaq: ENVX), a developer and manufacturer of advanced lithium-ion batteries, today announced that it will distribute warrants to purchase Enovix common stock (“Warrants”) to its stockholders and certain convertible noteholders on November 18, 2026 (the “Distribution Date”), in accordance with the previously declared stockholder warrant dividend. As previously announced, each stockholder of record as of the close of business on November 13, 2026 (the “Record Date”) will receive one (1) Warrant for every four (4) shares of Enovix common stock held, rounded down to the nearest whole Warrant.

 

“Our first warrant dividend in 2025 demonstrated the strong support of our stockholders and their interest in participating directly in Enovix’s growth,” said Ryan Benton, Interim Chief Executive Officer. “This distribution builds on that by giving investors another way to participate while helping us address our outstanding debt by permitting Warrant exercises with the delivery of our 3.00% Convertible Senior Notes due 2028 (the “2028 Notes”). Accepting our 2028 Notes at face value as payment of the exercise price allows us to retire debt and preserve cash for the business, while cash exercises provide additional funding that we could also apply toward retiring outstanding 2028 Notes and preserving flexibility to support execution on our priorities.”

 

Warrant Terms

 

Eligibility: Stockholders must have purchased or held shares no later than November 12, 2026 to be a stockholder of record as of the close of business on the November 13, 2026 Record Date and to receive Warrants.

 

Convertible Noteholders: Holders of our 2028 Notes and our 4.75% Convertible Senior Notes due 2030 (the “2030 Notes”) as of the Record Date will also receive Warrants on a pass-through basis, as provided under the applicable indentures, at the same one-for-four ratio.

 

Receipt of Warrants: Eligible recipients do not need to take any action or make any payment to receive their Warrants. Holders may exercise, hold or sell the Warrants. Holders whose securities are held through an intermediary should contact that intermediary with questions about when the Warrants will appear in their accounts.

 

Cash Exercise Price: Each Warrant entitles the holder to purchase one (1) share of Enovix common stock for $3.00 in cash, subject to adjustments and amendments under the warrant agreement.

 

Note Exercise Alternative: In lieu of cash, holders may exercise 333 Warrants by delivering $1,000 principal amount of 2028 Notes. Unless otherwise permitted by Enovix, the 2030 Notes may not be used to exercise the Warrants.

 

 

Listing: The Warrants are expected to begin trading separately from Enovix common stock on Nasdaq under the symbol ENVXW on November 19, 2026, subject to applicable approvals.

 

Scheduled Expiration: April 28, 2028, at 5:00 p.m. New York City time, subject to early expiration and any extension under the warrant agreement.

 

Early Expiration Price Condition: This condition will be satisfied if the daily volume-weighted average price (“VWAP”) of Enovix common stock equals or exceeds 110% of the then-applicable exercise price, initially $3.30, on twenty (20) trading days within any thirty (30) consecutive trading-day period following issuance (the “Early Expiration Price Condition”). The qualifying trading days need not be consecutive.

 

If the Early Expiration Price Condition is satisfied, the Warrants will expire at 5:00 p.m. New York City time on the business day immediately following the final qualifying trading day, or a later date selected by the Company in accordance with the warrant agreement. Enovix will announce the applicable expiration date by press release.

 

Exercise Using Cash or 2028 Notes

 

Beginning on the Distribution Date, holders may exercise their Warrants using cash or 2028 Notes, subject to the warrant agreement.

 

The 2028 Notes are designated as eligible for exercise. The 2030 Notes are not eligible and may not be delivered as payment. The Company may, in its discretion and subject to the notice requirements and other terms of the warrant agreement, change the debt securities designated as eligible for exercise.

 

For cash exercises, each Warrant entitles the holder to purchase one (1) share of Enovix common stock for $3.00. For exercises using 2028 Notes, holders may deliver $1,000 principal amount of 2028 Notes for every 333 Warrants exercised and receive 333 shares. Note exercises must be submitted in whole multiples of this ratio, regardless of the market price of the 2028 Notes.

 

For example, a holder delivering $20,000 principal amount of 2028 Notes may exercise 6,660 Warrants and receive 6,660 shares of common stock.

 

The ability to exercise Warrants with 2028 Notes is available to any investor holding 333 Warrants for each $1,000 principal amount of 2028 Notes delivered. Warrants may be acquired through the dividend distribution or in the open market. Any investor may purchase additional Warrants in the market for exercise, and certain qualifying investors may purchase additional 2028 Notes in market transactions.

 

Any 2028 Notes delivered and accepted for exercise of Warrants will be cancelled, reducing Enovix’s outstanding debt and associated future interest obligations without requiring the Company to use cash to repay that principal. Enovix will receive cash proceeds only from cash exercises of the Warrants. Any cash proceeds will be available for general corporate purposes, including retiring 2028 Notes.

 

2

 

Exercise Procedures and Investor Resources

 

Holders whose Warrants or 2028 Notes are held through a broker, bank or other intermediary should contact that intermediary regarding receipt of their Warrants, exercise instructions, permitted payment methods and applicable deadlines.

 

The early expiration feature could substantially shorten the exercise period. Holders should make arrangements with their intermediaries in advance, as intermediaries may impose deadlines earlier than the Company’s deadline. Warrants not exercised before the applicable expiration deadline will expire without value.

 

The warrant agreement, prospectus supplement and related investor materials describe the complete terms, including exercise procedures, adjustments to the Warrants, any exercise suspension provisions and the conditions governing early expiration. The warrant agreement and related registration documents were filed with the U.S. Securities and Exchange Commission (“SEC”) on November 18, 2026.

 

Additional information, including frequently asked questions, is available on the Company’s Investor Relations website at https://ir.enovix.com.

 

Transaction Advisors

 

B. Dyson Capital Advisors is serving as exclusive advisor to the Company on the structuring and distribution of the Warrants.

 

About Enovix

 

Enovix develops and manufactures advanced lithium-ion batteries, including proprietary silicon-anode architectures for smartphones, smart eyewear, defense, industrial and emerging edge-AI applications. Its proprietary silicon-anode battery architecture enables higher energy density and performance in space-constrained devices while maintaining safety and reliability, supporting commercialization across consumer and industrial markets.

 

Enovix is headquartered in Silicon Valley with facilities in India, South Korea and Malaysia, serving customers globally. For more information visit https://enovix.com and follow us on LinkedIn.

 

No Offer or Solicitation

 

This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

3

 

The issuance of the Warrants has not been registered under the Securities Act of 1933, as amended (the “Securities Act”), as the distribution of a Warrant for no consideration does not constitute a sale of a security under Section 2(a)(3) of the Securities Act. A registration statement on Form 8-A describing the terms of the Warrants, and a registration statement on Form S-3 and prospectus supplement relating to the issuance of shares of common stock upon exercise of the Warrants, have been filed with the SEC, and are available on the SEC’s website at www.sec.gov. Holders should read these materials carefully, including the Risk Factors section included and incorporated by reference therein. This press release contains a general summary of the Warrants. Please read the warrant agreement as it will contain important information about the terms of the Warrants.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial or operating performance and are identified by words such as anticipate, believe, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, will, would and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding: the terms of the Warrants, including the ability to exercise Warrants using cash or 2028 Notes and the scheduled expiration date and the Early Expiration Price Condition; the expected listing of the Warrants on Nasdaq and the existence of a trading market for the Warrants; the number of Warrants that may be exercised and the payment method holders may select; and the anticipated benefits to our balance sheet, interest obligations and liquidity of the Warrant distribution, as well as the anticipated use of additional funding that may be raised through cash exercises of the Warrants to support execution on our priorities. These statements are based on the current expectations of our management, are not predictions of actual performance, and actual results may differ materially from the future results, performance or achievements expressed or implied by the forward-looking statements.

 

Risks, uncertainties and assumptions that could cause actual results to differ materially from the results and events anticipated by such forward-looking statements include, but are not limited to: the possibility that few or no Warrants are exercised, or that holders elect to exercise Warrants primarily for cash or primarily with 2028 Notes (or the possibility that holders of 2028 Notes do not exercise Warrants by delivering 2028 Notes), such that the cash proceeds received or the debt retired differ materially from our expectations; the possibility that the Warrants are not approved for listing on Nasdaq or that an active trading market for the Warrants does not develop; the possibility that the Warrants expire without value, including because holders are unable to complete an exercise before any accelerated expiration deadline; volatility in the trading price of our common stock and the Warrants, including the possibility that the Early Expiration Price Condition is satisfied earlier or later than anticipated or not at all; and other risks described in the disclosures contained in our filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our annual report on Form 10-K and quarterly reports on Form 10-Q, and other documents that we have filed, or will file, with the SEC. These documents are available in the SEC Filings section of the Investor Relations page at https://ir.enovix.com and at www.sec.gov. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not rely on any of the forward-looking statements. Any forward-looking statements in this press release speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Contact

 

Monica Gould

Blueshirt Group

ir@enovix.com

 

4

 

Exhibit 99.2

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

● WARRANT DIVIDEND DISTRIBUTION

 

Stockholder FAQ

 

Frequently asked questions about the Enovix warrant dividend

 

Enovix Corporation (Nasdaq: ENVX) is distributing warrants to its stockholders and convertible noteholders at no cost. This FAQ explains what the warrants are, who receives them, how they can be exercised or sold, and what to expect between the record date and expiration. It is a summary only; the warrant agreement and our filings with the Securities and Exchange Commission (“SEC”) will govern.

 

● KEY TERMS AT A GLANCE

 

EXERCISE PRICE DISTRIBUTION RATIO
$3.00 per share 1 warrant per 4 shares
   
RECORD DATE DISTRIBUTION DATE
Friday, November 13, 2026 Wednesday, November 18, 2026
   
FIRST TRADING DAY NASDAQ TICKER
Thursday, November 19, 2026 ENVXW
   
EXPIRATION DATE EARLY EXPIRATION TRIGGER
April 28, 2028 $3.30 VWAP, 20 of 30 trading days

 

● IN THIS DOCUMENT

 

01  The Basics   02  How This Distribution Compares with 2025   03  Receiving Your Warrants
         
04  Exercise Price, Expiration and Early Expiration   05  Exercising Your Warrants   06  Trading the Warrants
         
07  Why This Structure   08  Tax Considerations   09  Other Questions

 

01 THE BASICS

 

 

What is a Warrant?

 

A warrant is an option to buy common shares issued directly by a company. Like any option, it gives the holder the right, but not the obligation, to purchase a share of common stock at a specified price (called the “exercise price”) before the warrant expires.

 

What is a Warrant Dividend?

 

A warrant dividend is the process of distributing warrants on a pro rata basis to our existing stockholders and convertible noteholders.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

1

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

Why is Enovix issuing these Warrants?

 

Enovix believes that a warrant dividend distribution is a stockholder-aligned approach to strengthening its balance sheet while giving existing stockholders and noteholders the opportunity to participate in the related equity issuance. Recipients can choose to exercise, hold or sell their warrants.

 

Building on the Company’s successful 2025 warrant dividend program, this distribution adds the ability to exercise warrants using the Company’s 3.00% Convertible Senior Notes due 2028 (the “2028 Notes”) at face value. 2028 Notes surrendered upon exercise will be cancelled, reducing outstanding debt and associated future interest obligations without requiring Enovix to use cash to repay that principal.

 

Cash exercises would provide additional liquidity for general corporate purposes. Together, these alternatives provide a path to retiring the 2028 Notes and cash generation while preserving cash for the business and putting the participation decision in each holder’s hands.

 

Who will receive the Warrants?

 

Holders of Enovix common stock as of the record date, November 13, 2026 (“stockholders”), will receive one warrant for every four (4) shares of common stock held, rounded down to the nearest whole number. No fractional warrants will be issued.

 

Holders of the 2028 Notes and the 4.75% Convertible Senior Notes due 2030 (the “2030 Notes”) as of the record date (“noteholders”) will also receive warrants on an as-converted pass-through basis in accordance with the terms of the governing agreements. As an example, holders of each $1,000 face amount of 2028 Notes will receive approximately 16 warrants, and holders of each $1,000 face amount of the 2030 Notes will receive approximately 22 warrants, in each case rounded down to the nearest whole number for any fractional warrant. No fractional warrants will be issued. Given this pass-through, the warrant distribution will not trigger a further adjustment to the conversion rate for the convertible notes.

 

When will the Warrants be distributed?

 

The Company expects to distribute the warrants to stockholders and noteholders on or about November 18, 2026 (the “distribution date”).

 

How many Warrants will be issued in total?

 

Including the effect of the Company’s repurchase and retirement of $128.0 million in aggregate principal amount of the 2030 Notes completed in October 2026, approximately 62.3 million warrants will be issued. This includes around 54.4 million warrants to common stockholders and an additional 7.9 million warrants to the noteholders, in accordance with the terms of those securities.

 

How much will be raised if all Warrants are exercised?

 

If all 62.3 million warrants are exercised at the $3.00 per share exercise price, Enovix would receive aggregate exercise consideration of approximately $169.1 million (excluding warrants held by our directors and executive officers), in a combination of cash and 2028 Notes surrendered at face value. The actual amount of proceeds Enovix can receive will depend on the number of warrants ultimately exercised (which will depend on, among other factors, the trading price of our common stock), the payment method selected by holders, and applicable transaction costs.

 

What do I have to do to receive the Warrants?

 

You must be an eligible stockholder or noteholder as of the record date to participate in the warrant distribution. The warrants will be issued without any action required by our equity holders and without any payment of cash or other consideration.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

2

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

If you hold shares or convertible notes through a brokerage account, bank, or financial institution and are a holder in street name, contact your broker for further information. If your shares are held in a registered account with Enovix’s transfer agent, contact Client Services at Computershare Trust Company, N.A.

 

What happens to fractional warrants?

 

Fractional warrants will not be issued or distributed. If a holder would otherwise be entitled to receive a fractional warrant, the total number of warrants issued to that holder will be rounded down to the nearest whole warrant. As a result, stockholders whose shareholdings are not evenly divisible by four will receive only whole warrants. For example, a stockholder owning 1, 100, or 145 shares of common stock would receive 0, 25, and 36 warrants, respectively.

 

Is management participating in the distribution?

 

All stockholders of record, including management stockholders, as of the November 13, 2026 record date are eligible to receive this distribution; however, our directors and executive officers will only realize value on the warrants (on a net exercise basis) if the warrants are in the money on the expiration date; and our directors and executive officers may not otherwise exercise, sell or transfer the warrants.

 

02 HOW THIS DISTRIBUTION COMPARES WITH 2025

 

 

How is this warrant distribution different from Enovix’s 2025 distribution?

 

This distribution builds on the success of our 2025 program with an added benefit: holders can exercise using cash or 2028 Notes at face value. The warrants can therefore do more than raise capital. They can also retire debt and reduce future interest obligations while keeping cash available for the business.

 

For stockholders, this combines the same opportunity to participate in Enovix’s future growth with the potential benefit of a stronger balance sheet. Holders retain the choice to exercise, hold or sell their warrants, with an additional way to fund their participation.

 

What were the results of the 2025 warrant dividend program?

 

Approximately 26.5 million warrants were exercised, generating approximately $232.1 million in gross proceeds. The program concluded on August 29, 2025, when all remaining warrants were either exercised or expired.

 

The program demonstrated substantial investor participation and provided additional capital to support Fab2 scale-up and general corporate purposes.

 

Why is Enovix undertaking another warrant distribution?

 

Enovix held approximately $512 million in cash, cash equivalents and investments, including restricted cash, as of October 4, 2026. This distribution gives us an opportunity to build on that liquidity by reducing outstanding debt and future interest obligations while keeping cash available to execute our business plans.

 

Following the strong investor participation in our 2025 program, we are again putting the opportunity to participate directly in existing stockholders’ and noteholders’ hands. The pro rata distribution gives stockholders the opportunity to maintain their proportional ownership on a fully-diluted basis by exercising their warrants if they choose to do so. This distribution also adds the ability to exercise using 2028 Notes at face value, which aligns with the stockholder opportunity to create a stronger balance sheet for the Company.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

3

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

How would this distribution reduce debt, raise cash and support the Company’s business?

 

Warrants exercised using 2028 Notes would retire the surrendered principal and reduce associated future interest obligations without requiring Enovix to use cash to repay that principal. Enovix would receive no cash proceeds from those exercises.

 

Warrants exercised for cash would provide additional liquidity for general corporate purposes, including a new source of funding for increasing the Company’s Korean drone battery manufacturing capacity without drawing on existing cash. Together, these payment methods give the Company a path to reduce debt and raise capital while preserving cash for business execution. The amount of debt retired and cash raised will depend on the number of warrants exercised and the payment methods selected by holders.

 

How much debt could Enovix retire if warrants are exercised using 2028 Notes?

 

The aggregate exercise price of all warrants being distributed (approximately $169.1 million) is approximately equal to the $172.5 million principal amount of 2028 Notes currently outstanding. If holders exercise a sufficient number of warrants using 2028 Notes, most of the $172.5 million of 2028 Notes could be retired. The actual amount retired will depend on how many warrants are exercised and whether holders choose to pay with cash or 2028 Notes.

 

03 RECEIVING YOUR WARRANTS

 

 

What’s the last day I can buy Enovix shares and still receive the warrants?

 

To receive the warrant dividend, you must purchase Enovix shares no later than the close of trading on November 12, 2026. Purchases made on or before November 12, 2026 should settle in time for you to be a stockholder of record on November 13, 2026, the official record date, and you should be eligible to receive the warrants.

 

If you buy shares on November 13, 2026 or later, your purchase will settle after the record date, and you will not receive any warrants. This is because November 13, 2026 is the ex-dividend date—the first trading day on which the shares no longer carry the right to receive the warrant dividend.

 

I purchased my Enovix shares through an online brokerage account. How will I receive my warrant notice or access the warrants?

 

Your broker is responsible for crediting your account with the warrants if you held shares as of the record date. You should not need to take action to receive them, but processing times vary. Please contact your broker directly for confirmation and additional information regarding timing and access to the warrants, including the mechanics of warrant sales and exercises.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

4

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

My warrants are not showing up in my brokerage account. What should I do?

 

Typically, your broker will be responsible for crediting your account with warrants if you held shares as of the record date and such shares are not being pledged as collateral or loaned out. If your shares are being pledged as collateral or loaned out, other mechanics may apply. In all cases you need to contact your broker directly for confirmation and for any other information regarding timing and access to warrants, including the mechanics for warrant sales and exercises.

 

What happens if I hold my Enovix shares in a margin account and the shares are on loan as of the November 13, 2026 record date?

 

If your Enovix shares are in a margin account, your broker may loan out your shares – often without notifying you. This is standard practice for margin accounts. If your shares are loaned out at the time of the warrant dividend record date, you are not considered the stockholder of record for purposes of receiving the warrant dividend and will not receive any warrants directly from Enovix.

 

If your broker has loaned out your shares, instead of receiving actual warrants from Enovix, your broker may instead post a placeholder entry in your account called an “in lieu of” credit. This “in lieu of” warrant credit does not represent an exercisable warrant and you will not be able to exercise or trade your warrant entry unless your broker takes steps to obtain the actual warrants for you, which is not guaranteed.

 

How do I ensure I receive the actual exercisable Enovix warrants if I have a margin account?

 

Transfer your shares from a margin account to a cash account (or a fully paid-for account) before the November 13, 2026 record date of the warrant dividend, and confirm with your broker that your shares will be held in your name and not subject to lending or rehypothecation. Processing time varies by broker.

 

Do non-U.S. stockholders qualify to receive the warrant dividend?

 

Yes. There are no stated restrictions on international stockholders receiving warrants. If you held Enovix common stock as of the record date through a brokerage account, you should receive the warrants in your account. If you are a non-U.S. stockholder, you should contact your broker for jurisdiction-specific logistics, including with regard to warrant sales and exercises.

 

I hold listed call options on Enovix common stock. Will I receive the warrant dividend?

 

No. Only holders of record of our common shares or convertible notes as of the November 13, 2026 record date will receive the warrant dividend. If you hold call options, you must exercise them and own the shares before the record date to receive warrants.

 

Option holders should also review any notices from the Options Clearing Corporation (“OCC”) to determine if there will be any adjustments to strike prices or deliverables. In connection with the distribution, listed call options may receive an “NS” (non-standard) designation on the record date. NS-designated options are not exercisable through automated systems and generally require manual exercise through your brokerage firm. Option holders should contact their brokerage firm for details regarding exercise procedures and timing.

 

How are the warrants handled for shares held in a retirement account?

 

Warrants will be credited to your retirement brokerage account if you held shares as of the record date. However, exercising or selling warrants from within a retirement account may be subject to additional rules or restrictions. Please consult your retirement account custodian or tax advisor.

 

What if I hold a short position?

 

If you are short Enovix stock as of the record date, you will be required on the distribution date to deliver the pro rata number of warrants to the lender of the shares you borrowed. As a result, market participants with short positions may need to purchase warrants in the open market to meet this delivery obligation.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

5

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

04 EXERCISE PRICE, EXPIRATION AND EARLY EXPIRATION

 

 

What is the Exercise Price?

 

Each warrant entitles the holder to purchase one share of Enovix common stock at an exercise price of $3.00. The exercise price may be paid in cash or by surrendering 2028 Notes at face value, as described in Section 05.

 

What is the Expiration Date?

 

The warrants will expire on April 28, 2028, unless the Early Expiration Price Condition is met.

 

What is the Early Expiration Price Condition?

 

If, during any 30 consecutive trading days, the volume-weighted average price (VWAP) of Enovix common stock is at or above $3.30 for at least 20 of those days (not necessarily consecutive), then the warrants will expire early — specifically at 5:00 p.m. New York City time on the business day immediately following that 30-day period or such other date as the Company may elect in accordance with the warrant agreement.

 

Enovix will issue a press release if the Early Expiration Price Condition is triggered.

 

When does the 20 out of 30-day VWAP measurement period for the Early Expiration Price Condition begin?

 

The 20 out of 30-day VWAP measurement period can begin on the first trading day after the distribution date. If Enovix shares are trading at or above $3.30 on that day and the VWAP meets the threshold, that day counts as the first of the 20 qualifying days within the 30-trading-day window.

 

If the VWAP Early Expiration Price Condition is met, for example, on the 20th qualifying day, when do the warrants expire?

 

The warrants will expire on the business day immediately following the 20th qualifying trading day within any 30-day period, unless the Company announces an alternate expiration date in accordance with the warrant agreement.

 

How will I know if the warrants are about to expire?

 

If the warrants are scheduled to expire, either on the final expiration date or due to early expiration, Enovix will issue a public press release announcing the expiration date. This notice will be made available as promptly as practicable and will include the exact date and time by which warrant exercises must be completed.

 

We encourage stockholders to monitor Enovix’s Investor Relations website (https://ir.enovix.com) for news announcements and updates, as well as our filings with the SEC at www.sec.gov.

 

Can my broker impose an earlier deadline to exercise than Enovix’s expiration time?

 

Yes. Your broker may require an earlier instruction deadline than the stated expiration time of the warrants and may require you to submit notices by specific methods. We recommend confirming your broker’s procedures, cut-offs and method of notice well in advance. Enovix also intends to issue a public press release reminder ahead of expiration.

 

What happens if the share price does not go up?

 

Holders may exercise their warrants at any time before expiration. If the stock price does not reach or exceed the early expiration price of $3.30 for 20 out of 30 consecutive trading days, the warrants will remain outstanding until their final expiration on April 28, 2028. If the stock never triggers early expiration, holders retain full control over their participation through the end of the term.

 

What happens if I do not exercise the warrants before they expire?

 

If you do not sell or exercise your warrants by the applicable expiration date, which may occur early as described above, such warrants will expire and have no value. Your rights under the warrants will lapse with no further action required or penalty.

 

You can choose to hold the warrants until expiration, sell them, or exercise them before expiration. If you take no action, the warrants simply expire. If other warrant holders exercise and new shares of common stock are issued to them while you do not exercise your warrants, your percentage ownership in Enovix’s common stock will decline.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

6

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

05 EXERCISING YOUR WARRANTS

 

 

When can I exercise my warrants?

 

You may exercise the warrants with cash at any time from the distribution date until 5:00 p.m. New York City time on the April 28, 2028 expiration date, or one business day after the date on which the Early Expiration Price Condition is reached (unless Enovix specifies an alternate expiration date as described in the warrant agreement).

 

You may also exercise the warrants with 2028 Notes at any time from the distribution date until the Early Exercise Expiration Price Condition is reached, as described in the warrant agreement.

 

How do I exercise my warrants?

 

If you hold the warrants through a brokerage account, bank or financial institution and are thus a holder in street name, you should contact your broker, bank or other financial institution intermediary for information on how to exercise warrants. You may also contact Computershare Trust Company, N.A., the warrant agent, at 150 Royall Street, Canton, MA 02021, Attention: Client Services, telephone 1-877-373-6374, if you have additional questions about the exercise process. You can pay with cash or 2028 Notes using the following methods.

 

To exercise for cash, you may instruct your broker to submit your exercise through the Depository Trust Company’s (“DTC”) WARR service and arrange payment of the cash exercise price.

 

To exercise using 2028 Notes, you may instruct your broker to submit your warrants and notes through DTC’s electronic system, known as ATOP. Computershare will review the submissions, and accepted exercises will settle on a weekly schedule. Accrued interest on accepted notes, calculated through the applicable allocation date, will be paid in cash along with your shares, based on the schedule in Exhibit C to the warrant agreement. Submission deadlines and settlement dates will be specified in the applicable DTC event announcements.

 

You can also exercise directly with Computershare, the warrant agent, using cash or 2028 Notes. For this method, you must submit a completed election to purchase warrant shares, included in Exhibit A to the warrant agreement, and arrange the applicable payment and delivery of securities. Your broker can arrange the required securities deliveries through DTC’s DWAC system, which allows securities to be transferred to and from the warrant agent. No separate accrued-interest payment is made for notes surrendered through this method.

 

If you are a direct registration holder, to exercise your warrants, you must provide payment to Computershare Trust Company, N.A. either (i) in United States dollars by certified or official bank check or wire transfer of immediately available funds to an account designated by Enovix or (ii) by the surrender of 2028 Notes having a face value, in each case, equal to $1,000 for every 333 warrants exercised. Such payment must specify the name of the holder and the number of warrants exercised. You also are required to present the election to purchase warrant shares attached to the warrant.

 

If you have any questions or cannot locate your warrant statement, please contact Computershare Trust Company, N.A., as warrant agent.

 

Please refer to the warrant agreement, including the section relating to “exercise terms” and the form of election to purchase warrant shares exhibit to the warrant agreement, which will be filed with the SEC together with the Form 8-A to register the warrants, at or prior to the distribution date.

 

How do I pay the exercise price, and how will the warrants be settled upon exercise?

 

The exercise price of the warrants is $3.00. A warrant holder may exercise their warrants at any time for cash, and exercises may be made with 2028 Notes, as will be specified under the terms in the warrant agreement. A warrant holder who surrenders 2028 Notes will be credited the $1,000 face value of those notes against the exercise price of the warrants, regardless of the notes’ trading price.

 

For purposes of payment of the exercise price, $1,000 principal amount of 2028 Notes shall be deemed to be equal to the aggregate exercise price for 333 warrants. Note exercises will be calculated using this fixed ratio, rather than by dividing the principal amount delivered by the cash exercise price, subject to adjustments provided in the warrant agreement. Only after the payment of the exercise price will holders receive shares of the Company’s common stock.

 

For example, a holder who exercises 333,000 warrants and delivers $1,000,000 face value of 2028 Notes will receive 333,000 shares. Holders of 2028 Notes who are not also stockholders of record may purchase additional warrants in the market in order to deliver a larger amount of their 2028 Notes to exercise warrants for shares of common stock.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

7

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

Can I purchase warrants or 2028 Notes in the open market to participate?

 

Yes. Holders of Enovix’s 2028 Notes may purchase additional warrants in the open market and exercise them using their notes. Stockholders who receive warrants in the distribution may also purchase 2028 Notes in the open market to pay the exercise price instead of cash. Other investors may purchase both warrants and 2028 Notes in the open market and submit them for exercise to receive Enovix common shares, in accordance with the warrant terms and exercise procedures.

 

Which Enovix notes are eligible for exercise?

 

Effective on the distribution date, notes of the following series issued by Enovix may be used to pay the exercise price:

 

TITLE OF SERIES  CUSIP / ISIN  PRINCIPAL
AMOUNT
OUTSTANDING
   CONSIDERATION PER $1,000
PRINCIPAL AMOUNT SURRENDERED
3.00% Convertible Senior Notes due 2028  293594AC1 / US293594AC17  $172,500,000   Warrant exercise price valued at the aggregate principal amount of the notes surrendered (regardless of the then-current market value of such notes), excluding any accrued and unpaid interest.

 

Enovix may add or remove the right to use a particular series of notes to pay the exercise price, provided that Enovix will give at least 20 business days’ notice before removing a series of notes from being eligible to pay the warrant exercise price. If we decide to add or remove notes, we will promptly make a public announcement, update our website and the corresponding table to reflect the change.

 

What happens if I surrender more in principal amount of notes than I exercise in warrants?

 

The principal amount of any 2028 Notes surrendered to exercise warrants in excess of the exercise price shall be forfeited to Enovix and will not be refunded unless the excess is greater than $1,000, in which case Enovix will return any notes in multiples of $1,000 principal amount pursuant to the terms of the warrant agreement.

 

If I use notes to pay for the exercise of the warrants, will I receive accrued interest?

 

If your broker submits your warrants and 2028 Notes through DTC’s ATOP system, accrued interest on the accepted notes, calculated through the applicable allocation date, will be paid in cash along with your shares on the weekly settlement date. The amount will be determined using the accrued-interest schedule in Exhibit C to the warrant agreement.

 

If you instead exercise directly with Computershare using the DWAC process, you will not receive a separate accrued-interest payment.

 

For notes surrendered after the coupon record date and before the corresponding coupon payment date, no separate accrued-interest payment will be made for the exercise. Instead, the normal coupon will be paid to the holder entitled to it as of the record date, in accordance with the applicable indenture.

 

Please confirm with your broker which exercise method to use.

 

06 TRADING THE WARRANTS

 

 

Will the Warrants trade publicly?

 

Yes. The warrants are expected to be listed on Nasdaq under the ticker symbol ENVXW and to begin trading on or about November 19, 2026, the first trading day after the distribution date.

 

Can I sell my Warrants?

 

Yes. The warrants are expected to be tradeable on Nasdaq. You can choose to hold, exercise, or sell them based on your financial objectives. Your ability to sell the warrants will depend, in part, on whether a trading market develops for the warrants.

 

07 WHY THIS STRUCTURE

 

 

Will this dilute my ownership?

 

There is no immediate dilution when we issue the warrants. New shares will only be issued if warrants are exercised and the Company receives the exercise price, in cash or in 2028 Notes. Unlike a traditional equity raise, this structure allows you to maintain your proportional ownership and avoid dilution by exercising your warrants.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

8

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

What will the Company use the proceeds for?

 

Enovix intends to use any cash proceeds from the exercise of the warrants for general corporate purposes, including reducing existing debt. Exercise of warrants in exchange for 2028 Notes will not result in any cash proceeds to Enovix but will reduce the amount of debt Enovix has outstanding and associated interest expense. In either event, we expect this to be a deleveraging transaction.

 

Why is the Company using this structure instead of a traditional equity raise?

 

The warrant dividend puts the opportunity to participate in the Company’s equity issuance directly in the hands of existing stockholders and noteholders. Recipients receive warrants in proportion to their existing holdings and can choose to exercise them, hold them or sell them to realize any available market value, without an obligation to invest additional funds.

 

The warrants serve two purposes: cash exercises would raise additional capital, while exercises using 2028 Notes at face value would retire outstanding debt and reduce associated future interest obligations without requiring Enovix to use cash to repay that principal. This gives the Company a path to both cash generation and debt reduction while preserving cash for the business and giving existing investors the opportunity to participate in its future growth.

 

Why would stockholders want this structure?

 

It gives our stockholders free optionality to choose what they want to do. Those who believe in our strategy gain the right, without any obligation, to buy more stock at a fixed, attractive price in the future. If we execute well, they benefit. If not, they’ve risked nothing. Holders also have the flexibility to sell their warrants and realize immediate value. We’re putting choice and timing in our stockholders’ hands.

 

Stockholders will also benefit from Enovix’s reduced leverage following the exercise of warrants with outstanding notes and from the Company’s increased cash position from warrants exercised with cash.

 

Our goal is to scale responsibly while protecting stockholder interests. This structure ensures capital is available when operational success justifies it, reinforcing long-term discipline and financial readiness, without pressuring the Company to raise funds under suboptimal conditions.

 

Why would noteholders want this structure?

 

Noteholders benefit as their 2028 Notes may be used to exercise warrants at the face value of the notes, regardless of the notes’ trading price. Upon exercise with the 2028 Notes, the leverage ratios of the Company will improve.

 

08 TAX CONSIDERATIONS

 

 

What are the tax implications?

 

The U.S. federal income tax consequences of the warrant dividend are complex and may vary based on each stockholder’s individual circumstances. Stockholders are encouraged to consult with their tax advisor to understand how the distribution may affect their individual tax situation.

 

For U.S. taxpayers, how will the warrant exercise be treated for tax purposes?

 

For U.S. taxpayers who receive warrants, this will generally not be a taxable event. However, if you exercise the warrants and later sell the resulting shares, you may incur capital gains taxes. In the event you exercise your warrants in exchange for shares, your cost basis for those shares will be the $3.00 exercise price, plus any transaction costs incurred.

 

The U.S. federal income tax treatment of the warrant distribution may vary based on an investor’s specific circumstances. Enovix does not provide tax advice. Investors are encouraged to consult their tax advisor regarding the potential impact of the distribution.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

9

 

 

WARRANT DIVIDEND FAQ    ●    NOVEMBER 2026

 

Additional details will be provided in the tax reporting section of the prospectus supplement, which Enovix expects to file with the SEC on the distribution date.

 

09 OTHER QUESTIONS

 

 

Are there risks to me of the warrants?

 

Yes. Like any security, the warrants involve risks. For example, they could expire with no value if not exercised, trading/liquidity may be limited, and early expiration can shorten the time to act. Please review the “Risk Factors” in Enovix’s prospectus supplement that we intend to file in connection with the warrants and our other filings with the SEC for a more detailed discussion.

 

Can Enovix change the terms of the warrants?

 

The procedures relating to any amendments or adjustments to the terms of the warrants will be set forth in the warrant agreement.

 

Can I receive a copy of the full warrant agreement?

 

Yes. Enovix expects to file the full warrant agreement with the SEC on or prior to the distribution date. It will be available via the SEC’s EDGAR system at www.sec.gov and on the Enovix Investor Relations page at ir.enovix.com.

 

Where can I find more information?

 

More information will be available in our investor presentation and our filings with the SEC. You may also contact Enovix Investor Relations at ir@enovix.com.

 

 

 

IMPORTANT INFORMATION

 

This document is provided for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities. The warrants and the shares of common stock issuable upon exercise will be offered pursuant to a registration statement on Form S-3 and a prospectus supplement filed with the SEC. Investors should read the prospectus supplement, the warrant agreement and Enovix’s other filings with the SEC, which contain important information, including risk factors, before making any investment decision. Statements regarding expected dates, amounts and outcomes are forward-looking and subject to change. Enovix does not provide tax, legal or investment advice; please consult your own advisors.

 

 

 

FORWARD-LOOKING STATEMENTS

 

This FAQ contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected record date, distribution date, listing and expiration of the warrants; the number of warrants to be issued; the number of warrants that may be exercised and the payment methods holders may select; the amount of cash raised or 2028 Notes retired; the expected benefits of the warrant dividend, including reduced debt and interest expense; the anticipated use of proceeds; and the expected tax treatment of the distribution. These statements are based on management’s current expectations and are not guarantees of future performance. Actual results may differ materially due to risks and uncertainties, including the possibility that few or no warrants are exercised, that the distribution is delayed or modified, or that the cash proceeds received or debt retired differ materially from our expectations; volatility in the trading price of our common stock and warrants; and the other risks described in the “Risk Factors” sections of our annual report on Form 10-K, our quarterly reports on Form 10-Q and the prospectus supplement relating to the warrants, each filed or to be filed with the SEC and available at https://ir.enovix.com and www.sec.gov. Forward-looking statements speak only as of the date of this document, and Enovix undertakes no obligation to update or revise them, whether as a result of new information, future events or otherwise.

 

ENOVIX CORPORATION    ●    NASDAQ: ENVX    ●    IR@ENOVIX.COM

10

 

Filing Exhibits & Attachments

7 documents

Keep reading